{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:18:59Z","timestamp":1765545539773,"version":"3.35.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00228-008-0587-2","type":"journal-article","created":{"date-parts":[[2008,11,17]],"date-time":"2008-11-17T07:04:26Z","timestamp":1226905466000},"page":"287-294","source":"Crossref","is-referenced-by-count":35,"title":["St John\u2019s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive"],"prefix":"10.1007","volume":"65","author":[{"given":"Liane","family":"Will-Shahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ullrich","family":"Kunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivar","family":"Roots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Brattstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,18]]},"reference":[{"key":"587_CR1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.313.7052.253","volume":"313","author":"K Linde","year":"1996","unstructured":"Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996) St John\u2019s wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ 313:253\u2013258","journal-title":"BMJ"},{"key":"587_CR2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/cp.1999.v66.a101944","volume":"66","author":"A Johne","year":"1999","unstructured":"Johne A, Brockm\u00f6ller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John\u2019s wort (Hypericum perforatum). Clin Pharmacol Ther 66:338\u2013345","journal-title":"Clin Pharmacol Ther"},{"key":"587_CR3","first-page":"A22","volume":"55","author":"A Maurer","year":"1999","unstructured":"Maurer A, Johne A, Bauer S, Brockm\u00f6ller J, Donath F, Roots I, Langheinrich M, H\u00fcbner WD (1999) Interaction of St John\u2019s wort extract with phenprocoumon. Eur J Clin Pharmacol 55:A22","journal-title":"Eur J Clin Pharmacol"},{"key":"587_CR4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1345\/aph.18252","volume":"33","author":"H Nebel","year":"1999","unstructured":"Nebel H, Schneider BJ, Baker RK, Kroll DJ (1999) Potential metabolic interaction between St John\u2019s wort and theophylline. Ann Pharmacother 33:502","journal-title":"Ann Pharmacother"},{"issue":"1","key":"587_CR5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00004714-200202000-00008","volume":"22","author":"A Johne","year":"2002","unstructured":"Johne A, Schmider J, Brockm\u00f6ller J, Stadelmann AM, St\u00f6rmer E, Bauer S, Scholler G, Langheinrich M, Roots I (2002) Decreased plasma levels of amitriptyline and its metabolites on co-medication with an extract from St. John\u2019s wort (Hypericum perforatum). J Clin Psychopharmacol 22(1):46\u201354","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"587_CR6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5414\/CPP38500","volume":"38","author":"I Mai","year":"2000","unstructured":"Mai I, Kr\u00fcger H, Budde K, Johne A, Brockm\u00f6ller J, Neumayer HH, Roots I (2000) Hazardous pharmacokinetic interaction of St John\u2019s wort with the immunosuppressant ciclosporin. Int J Clin Pharmacol Ther 38(10):500\u2013502","journal-title":"Int J Clin Pharmacol Ther"},{"key":"587_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(99)05712-8","volume":"355","author":"SC Piscitelli","year":"2000","unstructured":"Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John\u2019s wort [letter]. Lancet 355:547\u2013548","journal-title":"Lancet"},{"key":"587_CR8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(99)05712-8","volume":"355","author":"EMEA","year":"2000","unstructured":"EMEA (2000) Public statement on the risk of drug interactions with Hypericum perforatum (St John\u2019s wort) and antiretroviral medicinal products. Lancet 355:547\u2013548","journal-title":"Lancet"},{"key":"587_CR9","first-page":"2955","volume":"25","author":"KO Hiller","year":"2000","unstructured":"Hiller KO, Schmidt AH (2000) Chargenkonformit\u00e4t von Phytopharmaka. DAZ 25:2955\u20132961","journal-title":"DAZ"},{"key":"587_CR10","first-page":"3904","volume":"34","author":"M Wurglics","year":"2000","unstructured":"Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Schubert-Zsilavecz M (2000) Johanniskrautpr\u00e4parate. DAZ 34:3904\u20133910","journal-title":"DAZ"},{"issue":"6\/7","key":"587_CR11","first-page":"A16","volume":"56","author":"SC Mueller","year":"2000","unstructured":"Mueller SC, Uehleke B, Woehling H, Petzsch M, Riethling AK, Drewelow B (2000) Intraction of digoxin and herbal extracts from St John\u2019s wort depends on dose and formulation. Eur J Clin Pharmacol 56(6\/7):A16","journal-title":"Eur J Clin Pharmacol"},{"key":"587_CR12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.clpt.2004.01.014","volume":"75","author":"SC Mueller","year":"2004","unstructured":"Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EV, Sievers H, Frank B, Reithling AK, Drewelow B (2004) Effect of St John\u2019s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 75:546\u2013557","journal-title":"Clin Pharmacol Ther"},{"key":"587_CR13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2004.07.004","volume":"76","author":"I Mai","year":"2004","unstructured":"Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I (2004) Hyperforin content determines the magnitidue of the St John\u2019s wort-cyclosporine drug interaction. Clin Pharmacol Ther 76:330\u2013340","journal-title":"Clin Pharmacol Ther"},{"key":"587_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02850249","volume":"18","author":"B Meier","year":"2001","unstructured":"Meier B (2001) Comparing phytopharmaceuticals: the example of St John\u2019s wort. Adv Ther 18:35\u201346","journal-title":"Adv Ther"},{"key":"587_CR15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.0.CO;2-I","volume":"13","author":"E Schrader","year":"1998","unstructured":"Schrader E, Meier B, Brattstr\u00f6m A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 13:163\u2013169","journal-title":"Hum Psychopharmacol"},{"key":"587_CR16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004850-200015020-00001","volume":"15","author":"E Schrader","year":"2000","unstructured":"Schrader E (2000) Equivalence of St John\u2019s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15:61\u201368","journal-title":"Int Clin Psychopharmacol"},{"key":"587_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/bmj.321.7260.536","volume":"321","author":"H Woelk","year":"2000","unstructured":"Woelk H (2000) Comparison of St John\u2019s wort and imipramine for treating depression: randomised controlled trial. BMJ 321:536\u2013539","journal-title":"BMJ"},{"key":"587_CR18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0944-7113(00)80044-6","volume":"7","author":"JW Budzinski","year":"2000","unstructured":"Budzinski JW, Foster BC, Vanderhoek S, Arnasom JT (2000) An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273\u2013282","journal-title":"Phytomedicine"},{"key":"587_CR19","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1073\/pnas.130155097","volume":"97","author":"LB Moore","year":"2000","unstructured":"Moore LB, Goodwin B, Kones SA, Wisely GB, Serabit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St John\u2019s wort induces hepatic drug metabolism through activation of the pregnane X receptor. PNAS 97:7500\u20137502","journal-title":"PNAS"},{"key":"587_CR20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(24)39043-3","volume":"294","author":"RS Obach","year":"2000","unstructured":"Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St John\u2019s wort, an herbal preparation used in the treatment of depression. J Phar Exp Ther 294:88\u201395","journal-title":"J Phar Exp Ther"},{"key":"587_CR21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1067\/mcp.2000.106793","volume":"67","author":"CA Roby","year":"2000","unstructured":"Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) St John\u2019s wort: effect on CYP3A4 activity. Clin Pharmacol Ther 67:451\u2013457","journal-title":"Clin Pharmacol Ther"},{"key":"587_CR22","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/S0140-6736(99)00418-3","volume":"354","author":"E Ernst","year":"1999","unstructured":"Ernst E (1999) Second thoughts about safety of St John\u2019s wort. Lancet 354:2014\u20132016","journal-title":"Lancet"},{"key":"587_CR23","first-page":"843","volume":"90","author":"AE Raetz","year":"2001","unstructured":"Raetz AE, vonMoos M, Drewe J (2001) Johanniskraut: ein Phytopharmakon mit potentiell gef\u00e4hrlichen Interaktionen. Praxis 90:843\u2013849","journal-title":"Praxis"},{"key":"587_CR24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1046\/j.1365-2125.2003.02005.x","volume":"56","author":"A Pfrunder","year":"2003","unstructured":"Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J (2003) Interaction of St John\u2019s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 56:683\u2013690","journal-title":"Br J Clin Pharmacol"},{"key":"587_CR25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.clpt.2003.08.009","volume":"74","author":"SD Hall","year":"2003","unstructured":"Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John\u2019s wort and an oral contraceptive. Clin Pharmacol Ther 74:525\u2013535","journal-title":"Clin Pharmacol Ther"},{"key":"587_CR26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.contraception.2004.11.004","volume":"71","author":"PA Murphy","year":"2005","unstructured":"Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL (2005) Interaction of St John\u2019s wort with oral contraceptives: effects on the pharmacokinetics of norehindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71:402\u2013408","journal-title":"Contraception"},{"issue":"4","key":"587_CR27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-2005-864099","volume":"71","author":"G Arold","year":"2005","unstructured":"Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zeppelin HH, Friede M, Roots I (2005) No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John\u2019s wort extract. Planta Med 71(4):331\u2013337","journal-title":"Planta Med"},{"issue":"5","key":"587_CR28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2125.2006.02755.x","volume":"62","author":"DL Whitten","year":"2006","unstructured":"Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H (2006) The effect of St John\u2019s wort extracts on CY3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 62(5):512\u2013526","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"587_CR29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00210-007-0172-8","volume":"375","author":"U G\u00f6dtel-Armbrust","year":"2007","unstructured":"G\u00f6dtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L (2007) Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St John\u2019s Wort. Naunyn Schmidebergs Arch Pharmacol 375(6):377\u2013382","journal-title":"Naunyn Schmidebergs Arch Pharmacol"},{"issue":"1","key":"587_CR30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-4347(01)00390-5","volume":"765","author":"S Bauer","year":"2001","unstructured":"Bauer S, St\u00f6rmer E, Graubaum HJ, Roots I (2001) Determination of hyperforin, hypericin and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and UV detection. J Chromatogr B Biomed Sci Appl 765(1):29\u201335","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"587_CR31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0022-3565(24)37524-X","volume":"285","author":"O Hu","year":"1998","unstructured":"Hu O, Tang H, Lane H, Chang W, Hu T (1998) Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 285:955\u2013960","journal-title":"J Pharmacol Exp Ther"},{"key":"587_CR32","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockm\u00f6ller J, Bauer S, Roots I (1997) Cytochrome P 450 2D6 variants in a Caucasian population: allele frequencies and phenotype consequences. Am J Hum Genet 60:284\u2013295","journal-title":"Am J Hum Genet"},{"key":"587_CR33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0168-8278(95)80005-0","volume":"23","author":"KL Rost","year":"1995","unstructured":"Rost KL, Brockm\u00f6ller J, Esdorn F, Roots I (1995) Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 23:268\u2013277","journal-title":"J Hepatol"},{"key":"587_CR34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0014-2999(03)01481-X","volume":"466","author":"S Krusekopf","year":"2003","unstructured":"Krusekopf S, Roots I, Kleeber U (2003) Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CY-3A7 and CYP3A43. Eur J Pharmacol 466:7\u201312","journal-title":"Eur J Pharmacol"},{"key":"587_CR35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-006-0156-5","volume":"62","author":"Y B\u00f6ttiger","year":"2006","unstructured":"B\u00f6ttiger Y (2006) Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. Eur J Clin Pharmacol 62:621\u2013625","journal-title":"Eur J Clin Pharmacol"},{"key":"587_CR36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809502907-817","volume":"29","author":"B Kaplan","year":"1995","unstructured":"Kaplan B (1995) Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 29:736\u2013742","journal-title":"Ann Pharmacother"},{"key":"587_CR37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-3565(24)37890-5","volume":"287","author":"DM Gentile","year":"1998","unstructured":"Gentile DM, Verhoeven CHJ, Shimada T, Back DJ (1998) The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 287:975\u2013982","journal-title":"J Pharmacol Exp Ther"},{"key":"587_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-7824(91)90115-V","volume":"44","author":"V DeLeo","year":"1991","unstructured":"DeLeo V, Lanzetta D, Vanni AL, D\u2019Atona D, Severy FM (1991) Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 44:155\u2013161","journal-title":"Contraception"},{"key":"587_CR39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0010-7824(99)00025-6","volume":"59","author":"AM Heusden Van","year":"1999","unstructured":"Van Heusden AM, Fauser BC (1999) Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 59:237\u2013243","journal-title":"Contraception"},{"key":"587_CR40","volume-title":"Estrogens and progestogens in clinical practice","author":"JW Faigle","year":"1998","unstructured":"Faigle JW, Schenkel L (1998) Pharmacokinetics of estrogens and progestogens. In: Frazer IS (ed) Estrogens and progestogens in clinical practice. Churchill Livingstone, London"},{"key":"587_CR41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0010-7824(97)00030-9","volume":"55","author":"FZ Stanczyk","year":"1997","unstructured":"Stanczyk FZ (1997) Pharmacokinetics of the new progestogenes and influence of gestodene and desogestrel on ethinylestradiol metabolism. Contraception 55:273\u2013282","journal-title":"Contraception"},{"key":"587_CR42","unstructured":"Ereshefsky B, Gewertz N, Lam YWF, Vega LM, Ereshefsky L (1999) Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. NCDEU, 39th Ann. Meeting, Boca Raton, Florida, June 1\u20134, poster No. 130"},{"issue":"9","key":"587_CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0024-3205(99)00659-1","volume":"66","author":"JS Markowitz","year":"2000","unstructured":"Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC (2000) Effect of St John\u2019s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 66(9):133\u2013139","journal-title":"Life Sci"},{"issue":"1","key":"587_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-005-0061-3","volume":"62","author":"SC M\u00fcller","year":"2006","unstructured":"M\u00fcller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B (2006) The extent of induction of CYP3A by St. John\u2019s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 62(1):29\u201336","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0587-2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T20:04:28Z","timestamp":1738526668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0587-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,18]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0587-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2008,11,18]]}}}